Analytical Data
-
Gene name
CAPS
- Application
-
Alternative Names
CAPS;CAPS;CAPS1;KIAA1121;Calcium-dependent secretion activator 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13938
-
Expression Region
1-189aa
-
AA Sequence
MDAVDATMEK LRAQCLSRGA SGIQGLARFF RQLDRDGSRS LDADEFRQGL AKLGLVLDQA EAEGVCRKWD RNGSGTLDLE EFLRALRPPM SQAREAVIAA AFAKLDRSGD GVVTVDDLRG VYSGRAHPKV RSGEWTEDEV LRRFLDNFDS SEKDGQVTLA EFQDYYSGVS ASMNTDEEFV AMMTSAWQL
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CAPS (Calcium-dependent Activator Protein for Secretion) is a member of the CAPS family of proteins that plays a crucial role in the process of neurotransmitter release and hormone secretion in response to calcium signals. The significance of CAPS in exocytosis has drawn considerable attention in cellular and molecular biology research, as it acts as a key mediator in coupling calcium influx to vesicle fusion. Dysregulation of CAPS is associated with various neurological disorders, emphasizing the need for a deeper understanding of its molecular mechanisms. Recent studies have focused on the structural characterization of CAPS proteins and their interactions with other regulatory proteins, revealing insights into the calcium-dependent conformational changes that facilitate vesicle secretion. Additionally, researchers are exploring the potential of CAPS as a therapeutic target for conditions linked to altered secretion mechanisms, such as diabetes and neurodegenerative diseases. Overall, the ongoing research on CAPS and its role in cellular exocytosis aims to unravel the complexities of vesicular transport and secretion, providing a better understanding of physiological processes and potential avenues for drug development.











